Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Trastuzumab Stories

2013-06-28 12:24:26

SAN DIEGO, June 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Roche received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the subcutaneous formulation of Herceptin(®) (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with HER2-positive breast cancer in Europe. (Logo;...

2013-06-17 12:28:14

TORONTO, June 17, 2013 /CNW/ - Two of the world's most acclaimed cancer researchers, Drs. Tak Mak of the Princess Margaret Cancer Centre, and Dennis Slamon of the University of California, Los Angeles, will share news of a major research breakthrough, funded, in large part, through the generosity of donors. When: Tuesday, June 18, 2013 at 11 am sharp Where: Princess Margaret Cancer Centre 7th Floor, Research Atrium 610 University Avenue (south of...

2013-06-03 23:14:07

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. Chicago, Illinois (PRWEB) June 03, 2013 The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression...

2013-06-03 20:21:14

Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer ROCKVILLE, Md., June 3, 2013 /PRNewswire/ -- MacroGenics, Inc. announced that results of the first-in-human study of margetuximab were reported during an oral abstract session today at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Howard A. Burris, M.D., FACP, first author and Chief Medical Officer of Sarah Cannon Research Institute, presented "Phase 1 study of...

2013-06-03 12:32:40

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of...

2013-06-02 08:20:17

-- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1) EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor(®) (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior...

2013-05-31 12:21:41

Studies Submitted to ASCO Demonstrate Immunogenic Superiority of AE37 Over All Other Peptide Cancer Vaccines WORCESTER, Mass. and TORONTO, May 31, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today highlighted advantages of its AE37 cancer vaccine and technology in the context of a positive cancer immunotherapy forecast recently issued by Citigroup analysts. The Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com)...

2013-05-31 08:24:39

Prognostic Information from Oncotype DX in Metastatic Breast Cancer Indicates Importance of Biology Revealed by the Test Across Continuum of the Disease REDWOOD CITY, Calif., May 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 10 studies being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring the company's commitment to optimizing cancer treatment. New data include studies of the Oncotype DX®...

2013-05-30 08:28:12

-Array to Hold Conference Call to Discuss Collaboration on May 30 at 10 a.m. E.T.- SEATTLE and BOULDER, Colo., May 30, 2013 /PRNewswire/ -- Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor. HER2, also known as ErbB2, is a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers such...

2013-05-21 08:28:18

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 - 4:30 PM. The presentation will...